Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

GDC-0810 Pharmacokinetics and Transporter-Mediated Drug Interaction Evaluation with an Endogenous Biomarker in the First-in-Human, Dose Escalation Study.

Cheung KWK, Yoshida K, Cheeti S, Chen B, Morley R, Chan IT, Sahasranaman S, Liu L.

Drug Metab Dispos. 2019 Sep;47(9):966-973. doi: 10.1124/dmd.119.087924. Epub 2019 Jul 2.

2.

Correction to: Application of a Novel 'Make and Test in Parallel' Strategy to Investigate the Effect of Formulation on the Pharmacokinetics of GDC-0810 in Healthy Subjects.

Cheeti S, Hou HH, Nelson E, Walker H, Chen B, Morley R, Gates M, Musib L, Girish S, Sahasranaman S, Liu L.

Pharm Res. 2018 Oct 26;35(12):244. doi: 10.1007/s11095-018-2529-8.

PMID:
30367284
3.

Application of a Novel 'Make and Test in Parallel' Strategy to Investigate the Effect of Formulation on the Pharmacokinetics of GDC-0810 in Healthy Subjects.

Cheeti S, Hou HH, Nelson E, Walker H, Chen B, Morley R, Gates M, Musib L, Girish S, Sahasranaman S, Liu L.

Pharm Res. 2018 Oct 15;35(12):233. doi: 10.1007/s11095-018-2516-0. Erratum in: Pharm Res. 2018 Oct 26;35(12):244.

4.

Effect of OATP1B1/1B3 Inhibitor GDC-0810 on the Pharmacokinetics of Pravastatin and Coproporphyrin I/III in Healthy Female Subjects.

Liu L, Cheeti S, Yoshida K, Choo E, Chen E, Chen B, Gates M, Singel S, Morley R, Ware J, Sahasranaman S.

J Clin Pharmacol. 2018 Nov;58(11):1427-1435. doi: 10.1002/jcph.1261. Epub 2018 May 22.

PMID:
29786857
5.

Effect of Microenvironmental pH Modulation on the Dissolution Rate and Oral Absorption of the Salt of a Weak Acid - Case Study of GDC-0810.

Hou HH, Jia W, Liu L, Cheeti S, Li J, Nauka E, Nagapudi K.

Pharm Res. 2018 Jan 29;35(2):37. doi: 10.1007/s11095-018-2347-z.

PMID:
29380076
6.

Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment.

Abou-Alfa GK, Lewis LD, LoRusso P, Maitland M, Chandra P, Cheeti S, Colburn D, Williams S, Simmons B, Graham RA.

Cancer Chemother Pharmacol. 2017 Jul;80(1):29-36. doi: 10.1007/s00280-017-3315-8. Epub 2017 May 18.

7.

A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer.

Cheeti S, Budha NR, Rajan S, Dresser MJ, Jin JY.

Biopharm Drug Dispos. 2013 Apr;34(3):141-54. doi: 10.1002/bdd.1830. Epub 2013 Feb 26.

PMID:
23225350
8.

Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152).

Flygare JA, Beresini M, Budha N, Chan H, Chan IT, Cheeti S, Cohen F, Deshayes K, Doerner K, Eckhardt SG, Elliott LO, Feng B, Franklin MC, Reisner SF, Gazzard L, Halladay J, Hymowitz SG, La H, LoRusso P, Maurer B, Murray L, Plise E, Quan C, Stephan JP, Young SG, Tom J, Tsui V, Um J, Varfolomeev E, Vucic D, Wagner AJ, Wallweber HJ, Wang L, Ware J, Wen Z, Wong H, Wong JM, Wong M, Wong S, Yu R, Zobel K, Fairbrother WJ.

J Med Chem. 2012 May 10;55(9):4101-13. doi: 10.1021/jm300060k. Epub 2012 Mar 28.

9.

Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors.

Lorusso PM, Jimeno A, Dy G, Adjei A, Berlin J, Leichman L, Low JA, Colburn D, Chang I, Cheeti S, Jin JY, Graham RA.

Clin Cancer Res. 2011 Sep 1;17(17):5774-82. doi: 10.1158/1078-0432.CCR-11-0972. Epub 2011 Jul 13.

10.

Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding.

Graham RA, Lum BL, Cheeti S, Jin JY, Jorga K, Von Hoff DD, Rudin CM, Reddy JC, Low JA, Lorusso PM.

Clin Cancer Res. 2011 Apr 15;17(8):2512-20. doi: 10.1158/1078-0432.CCR-10-2736. Epub 2011 Feb 7.

11.

Determination of GDC-0449, a small-molecule inhibitor of the Hedgehog signaling pathway, in human plasma by solid phase extraction-liquid chromatographic-tandem mass spectrometry.

Ding X, Chou B, Graham RA, Cheeti S, Percey S, Matassa LC, Reuschel SA, Meng M, Liu S, Voelker T, Lum BL, Rudewicz PJ, Hop CE.

J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Mar 15;878(9-10):785-90. doi: 10.1016/j.jchromb.2010.01.039. Epub 2010 Feb 1.

PMID:
20172765
12.

The involvement of intracellular calcium in the MCT-mediated uptake of lactic acid by HeLa cells.

Cheeti S, Lee CH.

Mol Pharm. 2010 Feb 1;7(1):169-76. doi: 10.1021/mp900195c.

13.

Modifications of the isonipecotic acid fragment of SNS-032: analogs with improved permeability and lower efflux ratio.

Fan J, Fahr B, Stockett D, Chan E, Cheeti S, Serafimova I, Lu Y, Pham P, Walker DH, Hoch U, Choong IC.

Bioorg Med Chem Lett. 2008 Dec 1;18(23):6236-9. doi: 10.1016/j.bmcl.2008.09.099. Epub 2008 Oct 2.

PMID:
18926699
14.

A diaminocyclohexyl analog of SNS-032 with improved permeability and bioavailability properties.

Choong IC, Serafimova I, Fan J, Stockett D, Chan E, Cheeti S, Lu Y, Fahr B, Pham P, Arkin MR, Walker DH, Hoch U.

Bioorg Med Chem Lett. 2008 Nov 1;18(21):5763-5. doi: 10.1016/j.bmcl.2008.09.073. Epub 2008 Sep 24.

PMID:
18842409
15.

The role of monocarboxylate transporters in uptake of lactic acid in HeLa cells.

Cheeti S, Warrier BK, Lee CH.

Int J Pharm. 2006 Nov 15;325(1-2):48-54. Epub 2006 Jun 17.

PMID:
16887304

Supplemental Content

Loading ...
Support Center